{"filing":{"accession_number":"0001534969-26-000035","cik":"0001534969","ticker":"SERA","company_name":"SERA PROGNOSTICS, INC.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"sera-20260625.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000035/sera-20260625.htm"},"events":[{"id":15149,"run_id":13518,"accession_number":"0001534969-26-000035","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Mark Capone as a Class II director effective July 1, 2026, and his concurrent appointment to the Compensation Committee. The principal disclosed action is a person taking a role on the Board and a Board committee. While the filing also details compensatory arrangements (equity grants and cash compensation), the core event is the appointment itself, making exec_appointment the most salient classification. The appointment of an experienced healthcare executive with 40+ years in diagnostics and prior CEO experience at Myriad Genetics is material to investors assessing the company's governance and strategic direction.","company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12810,"accession_number":"0001534969-26-000035","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mark Capone as a Class II director effective July 1, 2026, and his concurrent appointment to the Compensation Committee. The principal disclosed action is a person taking a role on the Board and a Board committee. While the filing also details compensatory arrangements (equity grants and cash compensation), the core event is the appointment itself, making exec_appointment the most salient classification. The appointment of an experienced healthcare executive with 40+ years in diagnostics and prior CEO experience at Myriad Genetics is material to investors assessing the company's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:33:04.924120+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12810,"accession_number":"0001534969-26-000035","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Mark Capone as a Class II director effective July 1, 2026, and his concurrent appointment to the Compensation Committee. The principal disclosed action is a person taking a role on the Board and a Board committee. While the filing also details compensatory arrangements (equity grants and cash compensation), the core event is the appointment itself, making exec_appointment the most salient classification. The appointment of an experienced healthcare executive with 40+ years in diagnostics and prior CEO experience at Myriad Genetics is material to investors assessing the company's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:33:04.924120+00:00","company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","filing_date":"2026-06-30"}]}